Psyence Group Past Earnings Performance

Past criteria checks 0/6

Psyence Group's earnings have been declining at an average annual rate of -59.5%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-59.5%

Earnings growth rate

-44.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Psyence Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:PSYG.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-6640
31 Mar 240-6942
31 Dec 230-533
30 Sep 230-733
30 Jun 230-743
31 Mar 230-642
31 Dec 220-441
30 Sep 220-440
30 Jun 220-540
31 Mar 220-540
31 Dec 210-1550
30 Sep 210-1560
30 Jun 210-1550

Quality Earnings: PSYG.F is currently unprofitable.

Growing Profit Margin: PSYG.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PSYG.F is unprofitable, and losses have increased over the past 5 years at a rate of 59.5% per year.

Accelerating Growth: Unable to compare PSYG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSYG.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: PSYG.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies